Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3767244 | 0.84 | KDM4E (0.37) | BPTFHTR1ASLC6A2ADRB2NCF1 | |
| SCHEMBL194071 | 0.83 | BPTF (0.40) | BPTFHTR1ASLC6A2ADRB2NCF1 | |
| SCHEMBL7914693 | 0.82 | CHRNB2 (0.44) | BPTFHTR1ASLC6A2ADRB2NCF1 | |
| Fumaric Acid SCHEMBL3767240 | 0.73 | KDM4E (0.37) | BPTFHTR1ASLC6A2ADRB1CHRM2 | |
| Fumaric Acid SCHEMBL3767249 | 0.73 | KDM4E (0.37) | BPTFHTR1ASLC6A2ADRB1CHRM2 | |
| SCHEMBL194070 | 0.70 | BPTF (0.40) | BPTFHTR1ASLC6A2ADRB2NCF1 | |
| SCHEMBL195335 | 0.68 | BPTF (0.49) | BPTFHTR1AADRB2NCF1ADRB1 | |
| SCHEMBL16094581 | 0.68 | BRAF (0.44) | — | |
| SCHEMBL195203 | 0.68 | BPTF (0.51) | BPTFHTR1AADRB2NCF1ADRB1 | |
| SCHEMBL30282824 | 0.68 | BPTF (0.51) | BPTFHTR1AADRB2NCF1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-20140107103-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8637519-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8592400-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE12 | BPTF 2465/4885HTR1A 1137/4885SLC6A2 3634/4885 |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | SULT2A1, DPYD, HRH2 | BPTF 2045/4885HTR1A 1019/4885SLC6A2 4258/4885 |
| US-20140107103-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | HRH2, HRH1, HRH4 | BPTF 2037/4885HTR1A 954/4885SLC6A2 4319/4885 |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PTGER3 | BPTF 2442/4885HTR1A 714/4885SLC6A2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.